Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.5K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

330
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
330
Tumor Immunotherapy01:27

Tumor Immunotherapy

884
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
884
Development of Immunocompetence01:22

Development of Immunocompetence

590
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
590
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

549
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
549
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

80.3K
Overview
80.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biopsy-based Transcriptomics in Banff 2022 Antibody Mediated Rejection Categories.

Kidney international reports·2026
Same author

Impact of older donor age in kidney transplants in a biopsy-based observational study.

JCI insight·2026
Same author

Corrigendum to "Improving the histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants" [American Journal of Transplantation Volume 26, Issue 1, January 2026, Pages 117-130].

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Absolute and Fractional Donor-Derived Cell-Free DNA in the Follow-Up of Kidney Allograft Rejection.

HLA·2026
Same author

Single-Molecule Real-Time Sequencing for MUC1 Variable Number of Tandem Repeat Variation to Improve Autosomal Dominant Tubulointerstitial Kidney Disease Diagnosis.

Journal of the American Society of Nephrology : JASN·2026
Same author

Molecular diagnostics in HLA-incompatible kidney transplantation.

Transplantation reviews (Orlando, Fla.)·2026
Same journal

Introduction to pediatric solid organ transplantation - not just little adults!

Current opinion in organ transplantation·2026
Same journal

Editorial introduction.

Current opinion in organ transplantation·2026
Same journal

Precision medicine guided development of new immunosuppression strategies in solid organ transplantation.

Current opinion in organ transplantation·2026
Same journal

Intestinal transplantation for tumors.

Current opinion in organ transplantation·2026
Same journal

Current state of medical rehabilitation for adult short bowel syndrome patients with intestinal failure.

Current opinion in organ transplantation·2026
Same journal

Update on costimulatory blockade in transplantation: a review of recent literature.

Current opinion in organ transplantation·2026
See all related articles

Related Experiment Video

Updated: Nov 25, 2025

Murine Full-thickness Skin Transplantation
07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

20.8K

Developments in immunosuppression.

Ondrej Viklicky1,2, Janka Slatinska1, Marek Novotny1

  • 1Department of Nephrology, Transplant Center.

Current Opinion in Organ Transplantation
|December 17, 2020
PubMed
Summary
This summary is machine-generated.

Recent advancements in kidney transplant immunosuppression show promising results. New therapies like everolimus and monoclonal antibodies offer improved outcomes and reduced viral infections in transplant recipients.

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.2K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.7K

Related Experiment Videos

Last Updated: Nov 25, 2025

Murine Full-thickness Skin Transplantation
07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

20.8K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.2K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.7K

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation

Background:

  • Kidney transplantation is a vital treatment for end-stage renal disease.
  • Effective immunosuppression is crucial for long-term graft survival.
  • Managing side effects and infections remains a challenge in current immunosuppressive regimens.

Purpose of the Study:

  • To review recent achievements in immunosuppression for kidney transplant recipients.
  • To highlight novel therapeutic strategies and their clinical implications.
  • To discuss the impact of new findings on future immunosuppressive protocols.

Main Methods:

  • Review of scientific literature published within the last 18 months.
  • Analysis of clinical trial results for novel immunosuppressive agents.
  • Synthesis of data on efficacy, safety, and patient outcomes.

Main Results:

  • Everolimus-based immunosuppression demonstrated non-inferiority with reduced viral infections (CMV, BKV) compared to standard regimens.
  • Iscalimab, a CD40-inhibiting monoclonal antibody, has entered Phase II clinical studies.
  • Eculizumab (anti-C5 antibody) improved outcomes in antibody-mediated rejection and desensitization protocols.
  • Complement C1 inhibition is under investigation for antibody-mediated rejection.

Conclusions:

  • Emerging immunosuppressive strategies offer enhanced efficacy and safety profiles.
  • New treatments pave the way for improved outcomes in high-risk and sensitized kidney transplant recipients.
  • Future research will focus on optimizing immunosuppression to minimize viral infections and CNI nephrotoxicity.